Follow
"Patient groups and Eisai are upbeat but many doctors remain unconvinced and healthcare providers are restricting reimbursement. #Lecanemab, for all its landmark status, may end up representing a triumph of hope over evidence."
https://www.ft.com/content/34031d7e-909f-49c1-9550-cfcf36194fa2
